Pharma BD Deal Intelligence
Novo Nordisk acquired Forma Therapeutics for $1.1B for sickle cell disease and rare blood disorders.
Novo Nordisk acquires Forma Therapeutics for $1.1 billion to expand in sickle cell disease with etavopivat.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Novo Nordisk acquired Forma Therapeutics for USD 1.1B (USD 20/share cash; tender + merger), closing 14 Oct 2022, to enter sickle cell disease and rare blood disorders. The thesis centered on lead asset etavopivat, a first-in-class oral once-daily pyruvate kinase-R (PKR) activator. The thesis was validated in April 2026 when the pivotal Phase 3 HIBISCUS trial met both co-primary endpoints in SCD (27% reduction in vaso-occlusive crisis events; 48.7% of patients achieving a >1 g/dL haemoglobin increase at 24 weeks vs 7.2% on placebo, n=385). Novo Nordisk plans its first regulatory filing for etavopivat in H2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (this deal) | 2022 | $1.1B | 58 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2022 deals · Novo Nordisk A/S deals · Hematology deals